The US Food and Drug Administration (FDA) has approved Novo Nordisk’s new once-daily pill for weight management, designed to help people reduce excess body weight and maintain weight reduction over the long term. In clinical trials, patients achieved an average weight reduction of 16.6% from baseline. The therapy is also indicated to lower the risk of major cardiovascular events* such as heart attack and stroke in certain patients. Novo Nordisk expects to launch the pill in the United States in early January 2026.

JAKARTA, Indonesia, Jan. 28, 2026 /PRNewswire/ — The US Food and Drug Administration (FDA) has approved a once-daily oral GLP‑1 medicine to help people reduce excess body weight and maintain weight loss over the long term. The Novo Nordisk treatment marks a milestone in medical obesity care by offering the convenience of a pill with weight-loss results comparable to therapies that have typically required injections. The approval provides a new option for patients who need medical support for obesity but have been reluctant to use needles.

Data from the global OASIS 4 clinical trial showed the once-daily pill delivered significant weight-loss results. Participants lost an average of 16.6% of their starting body weight after about a year of consistent treatment.^[1] One in three patients achieved weight loss of more than 20%—a level that can translate into meaningful improvements in daily functioning and quality of life for people living with obesity. The findings suggest the oral option can deliver weight loss comparable to the once-weekly injectable version already available.

Beyond weight loss, the therapy is also approved to reduce the risk of serious heart and cardiovascular problems, including heart attack and stroke, in certain patient groups. Clinical data showed approximately a 20% reduction in cardiovascular risk among patients with heart disease who also have obesity or overweight. This means obesity management with this therapy addresses more than appearance—it offers meaningful protection for heart health and the potential to extend lifespan.

“The pill is here. With the approval of our once-daily oral GLP-1 treatment, patients will have a convenient pill option that can help them achieve weight loss comparable to injectable therapy,” said Mike Doustdar, president and CEO of Novo Nordisk. “As the first oral GLP-1 treatment for people living with overweight or obesity, this new option provides patients with a convenient choice to start or continue their weight loss journey. No other current oral GLP-1 treatment can match the weight loss results delivered by this therapy, and we are very excited for what this will mean for patients.”

The development has drawn attention as Indonesia faces a growing obesity challenge. According to the 2023 Indonesia Health Survey (Survey Kesehatan Indonesia, SKI), the obesity rate among adults has reached 23.4%—meaning roughly one in four adults lives with obesity. Central obesity, often reflected in abdominal fat, was recorded at 36.8% among people aged 15 and above. These conditions increase the risk of chronic diseases including type 2 diabetes, hypertension, heart disease and stroke. Beyond the health impact, obesity also carries an economic cost: a 2016 study by Bogor Agricultural University (IPB) estimated obesity-related losses in Indonesia at around tens of billions of rupiah annually when factoring in healthcare spending and productivity losses.

From Indonesia’s perspective, Sreerekha Sreenivasan, General Manager of Novo Nordisk Indonesia, emphasized that this breakthrough is a vital part of a long-term mission to transform obesity care. “In Indonesia, we are facing a critical rise in obesity, which frequently acts as a gateway to other life-threatening conditions like diabetes and heart disease. For many, lifestyle changes alone are not enough, and they deserve access to comprehensive medical support,” she stated. “The rapid pace of scientific innovation, including the innovation of GLP-1 therapies, proves that the medical community is now better equipped than ever to treat obesity as the serious chronic disease it is—moving the conversation far beyond personal appearance and toward long-term health and survival,” she added.

Sreenivasan emphasized that Novo Nordisk’s current focus in Indonesia is collaborating with healthcare professionals and other stakeholders to strengthen the understanding that obesity is a serious chronic disease requiring medical attention. “We are currently very focused on education, building healthcare capacity, and expanding access to existing treatments. At present, a once-weekly injectable GLP-1 therapy from Novo Nordisk is already available in Indonesia as a medical solution for patients,” she explained.

Experts emphasize that obesity is a complex, chronic disease—not simply the result of a lack of willpower or discipline. In people with obesity, hormonal systems that regulate hunger and fullness are often disrupted, causing the body to resist weight loss and defend a higher weight. GLP‑1–based treatments work by mimicking a natural hormone that acts on appetite centers in the brain, helping people feel fuller for longer, reduce food intake, and achieve gradual, more sustainable weight loss.

Although the GLP-1 pill is expected to reach the US market in early January 2026, the development signals where obesity treatment is heading globally. The public is encouraged to view obesity as a medical condition that deserves serious care— not simply a matter of personal appearance. People who struggle to lose weight, have abdominal obesity, or have been diagnosed with related conditions such as diabetes or hypertension are advised to consult a doctor for a comprehensive assessment and an appropriate treatment plan.

More information on obesity, its health risks, and evidence-based approaches to weight management is available on the educational website platform NovoCare.id. The site provides easy-to-understand resources for the public, including information on the role of modern treatments such as GLP‑1 therapies in supporting long-term obesity management.

Novo Nordisk’s GLP‑1 treatment for weight management is a prescription medicine prescribed by healthcare professionals following consultation. It is used alongside a reduced-calorie diet and increased physical activity to help adults with obesity or overweight manage their weight. Obesity is often accompanied by other conditions such as type 2 diabetes, high blood pressure, elevated blood lipids, heart disease, and joint pain. Clinical studies have demonstrated that GLP‑1–based weight management therapy can help many patients achieve significant weight loss and improve various risk factors associated with heart health and metabolic function.

About Novo Nordisk
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 78,500 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.id, Facebook, Instagram, X, LinkedIn, and YouTube. 

SINGAPORE, Jan. 28, 2026 /PRNewswire/ — Throughout 2025, Longbridge Securities continued to place technological innovation at the core of its strategy, and steadily expanded its global investment services. Beyond connecting investors to global markets, Longbridge further explored how investment can be integrated into everyday life. Building on its strong growth momentum, the annual user assets increased by 220% and the global user base grew by 120%. Outside Singapore, Longbridge Securities is the fastest-growing fintech brokerage in the Hong Kong market.

Solid growth across key business metrics, global user base increases by 120%

Against the backdrop of shifting global market conditions and evolving investor needs, Longbridge Securities achieved steady growth across several core business metrics in 2025. The annual user assets increased by 220% and the global user base grew by 120%. Furthermore, the total nominal order value reached US$1.5 trillion, with 55.7 million orders processed over the year. These results reflect the continued improvement of the platform in terms of trading infrastructure, product capabilities, and user trust.

Longbridge’s long-term investment in financial technology innovation and trading experience was also recognised through multiple industry awards, including the Asian Banking & Finance (ABF) FinTech Awards 2025: FinTech Innovation Award – Singapore, Asia FinTech Awards 2025: Investment Tech of the Year, Moneyhero Group Best of Awards 2025: Best Emerging Broker, as well as the EDigest 2025: Best Technology Innovation Broker, HKEJ: Financial Services Awards 2025 – Outstanding AI FinTech Brokerage, and the Hong Kong 01 FinTech Leadership Awards 2025 – AI Brokerage Platform. These accolades underscore market recognition of Longbridge’s technological capabilities and holistic service model.

Longbridge Group opens its first flagship store in Hong Kong, Longbridge Café

Longbridge Securities continued to expand the applications of investment services in 2025, supported by the Longbridge Group’s broader ecosystem strategy to better integrate investing into everyday life. This year, Longbridge Group opened its first brand flagship store, Longbridge Café, in Hong Kong. Through this, Longbridge is able to blend investment discussions with lifestyle settings, providing investors with a physical space for interaction and idea exchange.

Since its opening at the end of September, it has welcomed over 50,000 visitors, held over 20 investment sharing, communication and brand activities, and distributed over one million coffee coupons throughout its launch period. By extending financial services to physical life scenarios, Longbridge Café pioneered Asia’s first innovative venue, combining financial services with lifestyle experiences.

As the Longbridge Café operating model continues to mature, the Longbridge Group plans to further expand similar physical locations in Singapore and Hong Kong, extending the application of investment services in lifestyle scenarios and strengthening in-person connections within the investment community.

Continuous product iteration enhancing the AI-powered investing experience

Driven by user needs and trading efficiency, Longbridge continued to optimise its trading systems and product functions throughout 2025. During the year, both the desktop and mobile applications underwent more than 16 updates introducing and optimizing more than 110 features across multiple trading scenarios, including multi-leg options strategies, U.S. fractional shares and U.S. stocks recurring investment. User-focused benefits such as lifetime $0 commission trading, market data credits, options teaming and tiered fee structures further helped reduce trading costs.

Simultaneously, as one of the core intelligent products, PortAI underwent several significant upgrades during the year. It has evolved from an information-based tool to an investment assistant with reasoning capabilities and personalised memory. Throughout the year, PortAI has generated 57.3 million portfolio updates, responded to over 557,000 investment-related queries and analysed over 28,000 earning reports, helping users plan ahead and supporting their decision-making.

Community engagement has also continued to grow steadily, with the number of daily active users increasing by 120% year-on-year, generating over 760,000 posts and accumulating over 67 million views. Through these efforts, Longbridge has been able to form a vibrant investment community centered around market insights, trading experience, and strategy sharing.

Looking ahead: Strengthening Global Investment Infrastructure

Looking ahead, Longbridge Securities will continue to strengthen its focus on technological innovation, user experience and lowering barriers to investing. In pursuit of its vision to build the global trading infrastructure and network that delivers the best trading experiences, serving over 10% of retail investors worldwide, the company will continue to improve product functions and service scenarios to provide investors with a more efficient, transparent, and diversified investment journey. Committed to its mission of “Analyse Better, Trade Smarter, and everyone’s invited”, Longbridge Securities aims to empower users to make more confident investment decisions amid ever-changing market conditions.

About Longbridge Securities Singapore

Long Bridge Securities Pte. Ltd. (“Longbridge Securities Singapore” or “Longbridge Securities”, Co. Reg. No. 202111825D) is an AI-driven online brokerage focussing on supporting international trading through a dedicated global network and robust technical infrastructure. Founded in March 2019, Longbridge Securities holds a total of 22 financial licenses or regulatory approvals across markets including the United States, Hong Kong, and Singapore, and has raised over US$150 million from leading financial and investment institutions. Long Bridge Securities Pte. Ltd. is a licensed entity regulated by the Monetary Authority of Singapore (MAS) (Licence No. CMS 101211), holding a Capital Markets Services licence and operating as an Exempt Financial Adviser.

This advertisement has not been reviewed by the Monetary Authority of Singapore (MAS).

BEIJING, Jan. 28, 2026 /PRNewswire/ — Pony.ai, a global leader in achieving large-scale mass production and commercialization of autonomous driving technology, today announced a strategic partnership with Beijing ATBB Travel & Express Service Co., Ltd., a premium mobility service provider in China, as it continues to scale Robotaxi commercialization through an asset-light, partnership-driven model.

Under the collaboration, Pony.ai and ATBB will jointly deploy and operate Robotaxi services in China’s tier-1 cities, while also expanding the application of autonomous driving in airport and business travel scenarios. The partnership reflects Pony.ai’s broader asset-light strategy of accelerating Robotaxi deployment by working with established mobility operators that contribute fleet investment, service expertise and platform resources, supporting Robotaxi commercialization while improving capital efficiency, asset utilization and unit economics.

“We’re excited to partner with ATBB as we take another step forward in bringing autonomous driving into everyday transportation,” said Dr. James Peng, Founder and CEO of Pony.ai. “As autonomous driving technology matures, the challenge is no longer proving that it works, but deploying it efficiently and sustainably. By working with partners that bring deep mobility expertise and strong service capabilities, we can accelerate adoption, strengthen the economics of Robotaxi operations, and make fully driverless services a practical part of people’s daily journeys.”

“We’re pleased to be working with Pony.ai to combine our deep experience in premium mobility services with industry-leading fully driverless technology,” said Lixin Shao, Chairman of ATBB. “Through this partnership, we aim to help shape the next generation of intelligent mobility services, delivering a truly private, tailored and technology-driven Robotaxi experience for customers who value both quality and efficiency, while opening new opportunities in premium autonomous mobility.”

As part of the agreement, the two companies plan to jointly establish a Robotaxi fleet powered by Pony.ai’s seventh-generation Robotaxi vehicles. The fleet will operate in China’s tier-1 cities, including routes linking airports and high-speed rail stations. The jointly operated vehicles are expected to complement Pony.ai’s existing Robotaxi network, adding capacity and supporting a wide range of travel needs, from daily urban trips to airport transfers.

The initial Robotaxi fleet will be integrated into Pony.ai’s proprietary ride-hailing platform as well as third-party mobility ecosystems. Pony.ai will also integrate its self-operated Robotaxi vehicles into ATBB’s Xinghui Mobility platform, allowing both parties to share access to demand and fleet resources within a more flexible and scalable deployment framework.

The partnership will also deepen the deployment of autonomous driving in airport transfer and business travel scenarios. With fully driverless operations, Robotaxis offer a combination of on-time performance, enhanced privacy and customizable in-vehicle experiences. These features are expected to appeal to premium and business-class travelers, positioning Robotaxis as a differentiated mobility option for frequent business travelers who expect a higher standard of ground transportation.

The ATBB partnership builds on Pony.ai’s rapid progress in scaling commercial Robotaxi operations across China and internationally.

In 2025, Pony.ai achieved several major milestones, including securing China’s first citywide permit for fully driverless commercial Robotaxi operations in Shenzhen and expanding commercial services across Beijing, Guangzhou and Shanghai. The company’s total Robotaxi fleet has surpassed 1,159 vehicles, exceeding its fleet targets for 2025, and Pony.ai has announced plans to expand to more than 3,000 Robotaxis by the end of 2026.

Pony.ai has also reported that its Gen-7 Robotaxi operations reached city-wide unit economics breakeven in Guangzhou, reinforcing the commercial viability of its large-scale Robotaxi model. As more partners participate in fleet investment and operations, Pony.ai expects its asset-light approach to play an increasingly important role in supporting rapid and sustainable growth in both domestic and international markets.